These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 10704931

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of Dopamine Oxidation on Dopaminergic Neurodegeneration.
    Zhang S, Wang R, Wang G.
    ACS Chem Neurosci; 2019 Feb 20; 10(2):945-953. PubMed ID: 30592597
    [Abstract] [Full Text] [Related]

  • 6. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
    Guo Z, Xu S, Du N, Liu J, Huang Y, Han M.
    Neurosci Lett; 2016 Mar 11; 616():152-9. PubMed ID: 26827716
    [Abstract] [Full Text] [Related]

  • 7. Neuroprotection for Parkinson's disease: a new approach for a new millennium.
    Drukarch B, van Muiswinkel FL.
    Expert Opin Investig Drugs; 2001 Oct 11; 10(10):1855-68. PubMed ID: 11772291
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A, Muñoz P, Steinbusch HWM, Segura-Aguilar J.
    ACS Chem Neurosci; 2017 Apr 19; 8(4):702-711. PubMed ID: 28233992
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase.
    Graumann R, Paris I, Martinez-Alvarado P, Rumanque P, Perez-Pastene C, Cardenas SP, Marin P, Diaz-Grez F, Caviedes R, Caviedes P, Segura-Aguilar J.
    Pol J Pharmacol; 2002 Apr 19; 54(6):573-9. PubMed ID: 12866711
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease.
    Cai W, Wakamatsu K, Zucca FA, Wang Q, Yang K, Mohamadzadehonarvar N, Srivastava P, Tanaka H, Holly G, Casella L, Ito S, Zecca L, Chen X.
    Prog Neurobiol; 2023 Apr 19; 223():102414. PubMed ID: 36746222
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Novel Compound ITC-3 Activates the Nrf2 Signaling and Provides Neuroprotection in Parkinson's Disease Models.
    Lee JA, Son HJ, Park KD, Han SH, Shin N, Kim JH, Kim HR, Kim DJ, Hwang O.
    Neurotox Res; 2015 Nov 19; 28(4):332-45. PubMed ID: 26233727
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.